**Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia**

1. **Main Tables and Figures**

**Table 1** Genes and variants evaluated

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | **Genotyping Methods Utilized**  |
| **Gene** | **Star Allele** | **Variant** | **Nucleotide Changes** | **Effect On Protein** | **Allele Clinical Function Status** | **Nala PGx Core™** | **Agena VeriDose® Core and *CYP2D6* CNV Panel** | **TaqMan® DME Genotyping Assays** |
| ***CYP2C9*** | **\*2** | rs1799853 | 3608C>T | R144C | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| **\*3** | rs1057910 | 42614A>C | I359L | None | Bi-allelic Assay | VeriDose Core |   |
| ***CYP2C19*** | **\*2** | rs4244285 | 19154G>A | Splicing Defect | None | Bi-allelic Assay | VeriDose Core |   |
| **\*3** | rs4986893 | 17948G>A | W212X | None | Bi-allelic Assay | VeriDose Core |   |
| **\*17** | rs12248560 | -806C>T | 5' Region | Increased  | Bi-allelic Assay | VeriDose Core |   |
| ***CYP2D6*** | **\*2** | rs1135840 | 4181G>C  | S486T | Normal  | Bi-allelic Assay | VeriDose Core |   |
| **\*2** | rs16947 | 2851C>T  | R296C | Normal  | Bi-allelic Assay | VeriDose Core |   |
| **\*3** | rs35742686 | 2550delA | Frameshift | None | Bi-allelic Assay | VeriDose Core |   |
| **\*4** | rs3892097, rs1065852 | 1847G>A, 100C>T | Splicing Defect, P34S | None | Bi-allelic Assay | VeriDose Core |   |
| **\*5** | N/A | N/A | Gene Deletion | None | CNV Assay (Intron 2) | CYP2D6 CNV |   |
| **\*6** | rs5030655 | 1708delT | Frameshift | None | Bi-allelic Assay | VeriDose Core |   |
| **\*8** | rs5030865  | 1759G>T  | G169X | None | Tri-allelic Assay | VeriDose Core |   |
| **\*9** | rs5030656 | 2616delAAG  | K281del | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| **\*10** | rs3892097, rs1065852 | 1847G>A, 100C>T | Splicing Defect, P34S | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| **\*14** | rs5030865  | 1759G>A | G169R | Decreased  | Tri-allelic Assay | VeriDose Core |   |
| **\*21** | rs72549352 | 2580\_2581insC | Frameshift | None | Bi-allelic Assay | VeriDose Core |   |
| **\*29** | rs59421388 | 3184G>A  | V338M | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| **\*31** | rs267608319 | 4043G>A | R440H | None | Bi-allelic Assay | NA | AH21B9N |
| **\*35** | rs769258 | 31G>A  | V11M | Normal  | Bi-allelic Assay | NA | C\_\_27102444\_F0 |
| **\*36** | N/A | Recombination at Exon 9 | CYP2D6-2D7 Hybrid | None | CNV Assay (Exon 9) | CYP2D6 CNV |   |
| **\*41** | rs28371725 | 2989G>A  | Splicing Defect | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| ***SLCO1B1*** | **NA†**  | rs4149056 | g.52422T>C | V174A | Decreased  | Bi-allelic Assay | VeriDose Core |   |
| **†**Nala PGx Core™ detects the variant, rs4149056, which is associated with decreased enzymatic activity and is present in three known *SLCO1B1* haplotypes namely, *SLCO1B1\*5*, *SLCO1B1\*15* and *SLCO1B1\*17*. |

**Table 2** Observed genotype-level call rates per variant per gene per platform

|  |  |  |
| --- | --- | --- |
| **Gene** | **Variant** | **Variant Call Rate, % (n=246)** |
| **Nala PGx Core™** | **Agena VeriDose® Core and *CYP2D6* CNV Panel** | **TaqMan® DME Genotyping Assays** |
| ***CYP2C9*** | rs1799853 | 100.0 | 99.2 | NA |
|   | rs1057910 | 100.0 | 99.6 | NA |
| ***CYP2C19*** | rs4244285 | 100.0 | 99.6 | NA |
|   | rs4986893 | 100.0 | 99.6 | NA |
|   | rs12248560 | 100.0 | 98.8 | NA |
| ***CYP2D6*** | rs1065852 | 98.4 | 95.9 | NA |
|   | rs5030655 | 100.0 | 99.2 | NA |
|   | rs3892097 | 98.8 | 99.2 | NA |
|   | rs35742686 | 100.0 | 98.8 | NA |
|   | rs16947 | 100.0 | 99.6 | NA |
|   | rs28371725 | 100.0 | 99.2 | NA |
|   | rs1135840 | 100.0 | 99.6 | NA |
|   | rs769258 | 98.8 | NA | 100.0 |
|   | rs5030865 | 97.2 | 99.2 | NA |
|   | rs5030656 | 100.0 | 99.6 | NA |
|   | rs59421388 | 100.0 | 99.2 | NA |
|   | rs267608319 | 99.6 | NA | 100.0 |
|   | CNV Assay (Intron 2) | 99.6 | 99.2 | NA |
|   | CNV Assay (Exon 9) | 99.6 | 99.2 | NA |
| ***SLCO1B1*** | rs4149056 | 100.0 | 99.2 | NA |

**Table 3** Observed diplotype-level call rates per gene per platform

|  |  |
| --- | --- |
| **Gene** | **Diplotype Call Rate, % (n=246)** |
| **Nala PGx Core™** | **Agena VeriDose® Core and *CYP2D6* CNV Panel** |
| ***CYP2C9*** | 100.0 | 97.2 |
| ***CYP2C19*** | 100.0 | 98.8 |
| ***CYP2D6*** | 95.9 | 90.7 |

**Table 4** Intra-precision and inter-precision concordance rates

|  |  |  |
| --- | --- | --- |
| **Gene** | **Variant** | **Concordance rate, %**  |
| **Intra-precision** | **Inter-precision** |
| **(47 tests in triplicate)** | **(120 tests across 4 variables)** |
| ***CYP2C9*** | rs1799853 | 100% | 100% |
| rs1057910 | 100% | 100% |
| ***CYP2C19*** | rs4244285 | 100% | 100% |
| rs4986893 | 100% | 100% |
| rs12248560 | 100% | 100% |
| ***CYP2D6*** | rs1065852 | 100% | 100% |
| rs5030655 | 100% | 100% |
| rs3892097 | 100% | 100% |
| rs35742686 | 100% | 100% |
| rs16947 | 100% | 100% |
| rs28371725 | 100% | 100% |
| rs1135840 | 100% | 100% |
| rs769258 | 100% | 100% |
| rs5030865 | 100% | 100% |
| rs5030656 | 100% | 100% |
| rs59421388 | 100% | 100% |
| rs267608319 | 100% | 100% |
| ***SLCO1B1*** | rs4149056 | 100% | 100% |

**Table 5** Intra-precision and inter-precision for *CYP2D6* Copy Number

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Sample** | **Variant** | **Average Copy Number** | **Sample Size, n** | **Coefficient of Variation** |
| **Intra-precision** | **Inter-precision** |
| 221374 | Intron 2 | 2 | 11 | 4% | 6% |
|   | Exon 9 | 1 |   | 5% | 5% |
| 222660 | Intron 2 | 2 | 9 | 3% | 5% |
|   | Exon 9 | 2 |   | 4% | 6% |
| 222769 | Intron 2 | 3 | 22 | 4% | 10% |
|   | Exon 9 | 2 |   | 6% | 13% |

**Table 6** Genotype concordance for genes *CYP2C9*, *CYP2C19*, *CYP2D6* and *SLCO1B1*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Variant** | **Genotype** | **Sample Size Per Genotype†** | **Concordance to Benchmark, %‡** | **Discordant Calls By** **Nala PGx Core™**§ |
|  |
| ***CYP2C9*** | **rs1799853** | C/C | 212 | 100.0 | 0 |  |
|  | N = 225 | C/T | 13 |   | 0 |  |
|  |  | T/T | 0 |   | 0 |  |
|  | **rs1057910** | A/A | 204 | 100.0 | 0 |  |
|  | N = 225 | A/C | 21 |   | 0 |  |
|  |   | C/C | 0 |   | 0 |  |
| ***CYP2C19*** |  **rs4244285** | G/G | 121 | 96.9 | 1 |  |
|  | N = 225 | A/G | 89 |   | 2 |  |
|  |  | A/A | 15 |   | 4 |  |
|  | **rs4986893** | G/G | 206 | 98.7 | 2 |  |
|  | N = 225 | A/G | 19 |   | 1 |  |
|  |  | A/A | 0 |   | 0 |  |
|  | **rs12248560** | C/C | 0 | 100.0 | 0 |  |
|  | N = 225 | C/T | 0 |   | 0 |  |
|  |   | T/T | 0 |   | 0 |  |
| ***CYP2D6*** | **rs1065852** | G/G | 77 | 99.6 | 0 |  |
|  | N = 225 | A/G | 76 |   | 1 |  |
|  |  | A/A | 72 |   | 0 |  |
|  | **rs5030655** | A/A | 224 | 100.0 | 0 |  |
|  | N = 225 | delA/A | 1 |   | 0 |  |
|  |  | delA/delA | 0 |   | 0 |  |
|  | **rs3892097** | C/C | 205 | 100.0 | 0 |  |
|  | N = 225 | C/T | 16 |   | 0 |  |
|  |  | T/T | 4 |   | 0 |  |
|  | **rs35742686** | T/T | 225 | 100.0 | 0 |  |
|  | N = 225 | delT/T | 0 |   | 0 |  |
|  |  | delT/delT | 0 |   | 0 |  |
|  | **rs16947** | G/G | 145 | 96.9 | 2 |  |
|  | N = 225 | A/G | 64 |   | 4 |  |
|  |  | A/A | 16 |   | 1 |  |
|  | **rs28371725** | C/C | 204 | 100.0 | 0 |  |
|  | N = 225 | C/T | 19 |   | 0 |  |
|  |  | T/T | 2 |   | 0 |  |
|  | **rs1135840** | C/C | 33 | 97.8 | 1 |  |
|  | N = 225 | C/G | 68 |   | 1 |  |
|  |  | G/G | 124 |   | 3 |  |
|  | **rs769258** | C/C | 220 | 100.0 | 0 |  |
|  | N = 225 | C/T | 5 |   | 0 |  |
|  |  | T/T | 0 |   | 0 |  |
|  | **rs5030865** | C/C | 222 | 99.6 | 0 |  |
|  | N = 225 | C/T | 3 |   | 1 |  |
|  |  | T/T | 0 |   | 0 |  |
|  | **rs5030656** | CTT/CTT | 224 | 100.0 | 0 |  |
|  | N = 225 | delCTT/CTT | 1 |   | 0 |  |
|  |  | delCTT/delCTT | 0 |   | 0 |  |
|  | **rs59421388** | C/C | 224 | 100.0 | 0 |  |
|  | N = 225 | C/T | 1 |   | 0 |  |
|  |  | T/T | 0 |   | 0 |  |
|  | **rs267608319** | C/C | 225 | 100.0 | 0 |  |
|  | N = 225 | C/T | 0 |   | 0 |  |
|  |   | T/T | 0 |  | 0 |  |
| ***SLCO1B1*** | **rs4149056** | T/T | 182 | 97.3 | 2 |  |
|  | N = 225 | C/T | 42 |   | 4 |  |
|   |   | C/C | 1 |   | 0 |  |
| †”Sample Size Per Genotype” reflects the counts of each genotype as produced by the benchmark, and not by Nala PGx Core™.**‡**Refer to Table 1 for an outline of the benchmark methods used per variant.§Discordant calls refer to instances in which Nala PGx CoreTM did not produce a genotype call concordant with the benchmark. |  |
|  |

**Table 7** Genotype concordance for *CYP2D6* Intron 2 And Exon 9 Copy Number Variations

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Variant** | **Copy Number** | **Sample Size Per Copy Number†** | **Concordance to Benchmark, %‡** | **Discordant Calls By** **Nala PGx Core™**§ |
|
| ***CYP2D6*** | **Intron 2** | 0 | 0 | 99.6 | 0 |
|   | N = 224 | 1 | 12 |   | 0 |
|   |  | 2 | 130 |   | 0 |
|   |  | >=3 | 82 |   | 1 |
|   | **Exon 9** | 0 | 0 | 98.7 | 0 |
|   | N = 224 | 1 | 24 |   | 1 |
|   |  | 2 | 193 |   | 2 |
|   |   | >=3 | 7 |   | 0 |
| †”Sample Size Per Copy Number” reflects the counts of each copy number call as produced by the benchmark, and not by Nala PGx Core™**‡**Refer to Table 1 for an outline of the benchmark methods used per variant.§Discordant calls refer to instances in which Nala PGx CoreTM did not produce a copy number call concordant with the benchmark. |

**Table 8** Diplotype concordance for *CYP2C9*, *CYP2C19* and *CYP2D6* between Nala PGx Core™, and Agena VeriDose® Core and *CYP2D6* CNV Panel

|  |  |  |
| --- | --- | --- |
| **Genes** | **Concordance, %**† | **Discordant Diplotypes** |
| **Agena VeriDose® Core and *CYP2D6* CNV Panel** | **Nala PGx Core™** | **Instances** |
| ***CYP2C9*** | 100% (n = 213) | NA | NA | NA |
| ***CYP2C19*** | 96.4% (n = 223) | \*1/\*1 | \*1/\*3 | 1 |
|  |  | \*1/\*2 | \*1/\*1 | 1 |
|  |  | \*1/\*2 | \*1/\*3 | 1 |
|  |  | \*1/\*3 | \*2/\*2 | 1 |
|  |  | \*2/\*2 | \*1/\*1 | 2 |
|  |  | \*2/\*2 | \*1/\*2 | 2 |
| ***CYP2D6*** | 94.7% (n = 209) | \*1/\*1 | \*2/\*2 | 1 |
|  |  | \*1/\*10 | \*1/\*10, CN >=3 | 1 |
|  |  | \*1/\*41 | \*39/\*41 | 1 |
|  |  | \*2/\*2 | \*1/\*1 | 1 |
|  |  | \*2/\*10 | \*1/\*10 | 1 |
|  |  | \*2/\*36, CN >=3 | \*2/\*10, CN >=3 | 1 |
|  |  | \*4/\*36 | \*4/\*10 | 2 |
|  |  | \*10/\*36 | \*2/\*36 | 1 |
|  |  | \*13 \*1/\*10 | \*1/\*10, CN >=3 | 1 |
|  |  | \*13 \*1/\*41, CN = 1 | \*1/\*41 | 1 |
| †The concordance presented in this table excludes samples that have mismatches in diplotype calls arising from technological differences between platforms. Please refer to Supplementary Table 7 for a detailed breakdown of all diplotypes detected. |

**Table 9** Observed allele frequencies by ethnicity

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Gene** | **Allele or Variant** |  | **Allele Frequencies (Per This Study)** | **Allele Frequencies (PharmGKB)** |
| **Indonesian** | **Chinese** | **Malay** | **Indian** | **Caucasian** | **Overall** | **East Asian** | **Central/****South Asian** | **European** |
| ***CYP2C9*****(n = 206)** | **\*2** | 0.000 | 0.000 | 0.000 | 0.060 | 0.172 | 0.032 | 0.002 | 0.114 | 0.127 |
| **\*3** | 0.000 | 0.040 | 0.039 | 0.100 | 0.069 | 0.044 | 0.038 | 0.110 | 0.076 |
| ***CYP2C19*****(n = 201)** | **\*2** | 0.297 | 0.274 | 0.289 | 0.229 | 0.138 | 0.256 | 0.284 | 0.270 | 0.147 |
| **\*3** | 0.041 | 0.055 | 0.066 | 0.000 | 0.017 | 0.042 | 0.072 | 0.016 | 0.002 |
| **\*17** | 0.054 | 0.007 | 0.039 | 0.229 | 0.138 | 0.067 | 0.021 | 0.171 | 0.216 |
| ***CYP2D6*****(n = 195)** | **\*2** | 0.088 | 0.118 | 0.167 | 0.140 | 0.196 | 0.136 | 0.121 | 0.295 | 0.277 |
| **\*4** | 0.000 | 0.035 | 0.069 | 0.020 | 0.161 | 0.051 | 0.005 | 0.091 | 0.185 |
| **\*5** | 0.029 | 0.028 | 0.028 | 0.080 | 0.000 | 0.031 | 0.049 | 0.046 | 0.030 |
| **\*6** | 0.000 | 0.000 | 0.000 | 0.000 | 0.018 | 0.003 | 0.000 | 0.000 | 0.011 |
| **\*9** | 0.000 | 0.000 | 0.000 | 0.000 | 0.018 | 0.003 | 0.002 | 0.003 | 0.028 |
| **\*10** | 0.338 | 0.299 | 0.222 | 0.160 | 0.143 | 0.251 | 0.436 | 0.087 | 0.016 |
| **\*14** | 0.000 | 0.014 | 0.000 | 0.000 | 0.000 | 0.005 | 0.003 | ND | 0.000 |
| **\*29** | 0.000 | 0.000 | 0.000 | 0.000 | 0.018 | 0.003 | 0.000 | 0.003 | 0.001 |
| **\*36** | 0.206 | 0.250 | 0.181 | 0.160 | 0.054 | 0.190 | 0.012 | 0.000 | 0.000 |
| **\*41** | 0.044 | 0.056 | 0.028 | 0.040 | 0.071 | 0.049 | 0.023 | 0.123 | 0.092 |
| ***SLCO1B1*****(n = 203)** | **rs4149056†** | 0.125 | 0.074 | 0.026 | 0.040 | 0.167 | 0.084 | 0.125‡ | 0.050‡ | 0.159‡ |
| "ND" refers to instances in which no data is available for the given allele on PharmGKB.†rs4149056 refers to the reduced function variant of *SLCO1B1* that is present in *SLCO1B1\*5*, *SLCO1B1\*15* and *SLCO1B1\*17*.‡Allele frequency values for rs4149056 have been obtained from gnomAD. |

**Figure 1.** ***CYP2D6\*36* Frequency By Ethnicity.** Distribution of individuals carrying one or two copies of the *CYP2D6\*36* allele among the study cohort (n=205), grouped per ethnicity

**Table 10** Observed diplotype frequencies by ethnicity

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Diplotype** | **Phenotype‡** |  |  | **Diplotype Frequencies (Per This Study)†** |
| **Indonesian** | **Chinese** | **Malay** | **Indian** | **Caucasian** | **Overall** |
| **Obs** | **Freq** | **Obs** | **Freq** | **Obs** | **Freq** | **Obs** | **Freq** | **Obs** | **Freq** | **Obs** | **Freq** |
| ***CYP2C9*** | **\*1/\*1** | NM | 39 | 1.000 | 69 | 0.920 | 35 | 0.921 | 17 | 0.680 | 16 | 0.552 | 176 | 0.854 |
|  | **\*1/\*2** | IM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 3 | 0.120 | 9 | 0.310 | 12 | 0.058 |
|  | **\*1/\*3** | IM | 0 | 0.000 | 6 | 0.080 | 3 | 0.079 | 5 | 0.200 | 3 | 0.103 | 17 | 0.083 |
|  | **\*2/\*3** | PM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.034 | 1 | 0.005 |
| ***CYP2C19*** | **\*1/\*1** | NM | 10 | 0.270 | 31 | 0.425 | 14 | 0.368 | 8 | 0.333 | 14 | 0.483 | 77 | 0.383 |
|  | **\*1/\*2** | IM | 19 | 0.514 | 28 | 0.384 | 14 | 0.368 | 5 | 0.208 | 7 | 0.241 | 73 | 0.363 |
|  | **\*1/\*3** | IM | 3 | 0.081 | 6 | 0.082 | 3 | 0.079 | 0 | 0.000 | 1 | 0.034 | 13 | 0.065 |
|  | **\*1/\*17** | RM | 3 | 0.081 | 1 | 0.014 | 1 | 0.026 | 5 | 0.208 | 5 | 0.172 | 15 | 0.075 |
|  | **\*2/\*2** | PM | 1 | 0.027 | 5 | 0.068 | 3 | 0.079 | 1 | 0.042 | 0 | 0.000 | 10 | 0.050 |
|  | **\*2/\*3** | PM | 0 | 0.000 | 2 | 0.027 | 2 | 0.053 | 0 | 0.000 | 0 | 0.000 | 4 | 0.020 |
|  | **\*2/\*17** | IM | 1 | 0.027 | 0 | 0.000 | 0 | 0.000 | 4 | 0.167 | 1 | 0.034 | 6 | 0.030 |
|  | **\*17/\*17** | UM | 0 | 0.000 | 0 | 0.000 | 1 | 0.026 | 1 | 0.042 | 1 | 0.034 | 3 | 0.015 |
| ***CYP2D6*** | **\*1/\*1** | NM | 6 | 0.176 | 7 | 0.097 | 5 | 0.139 | 4 | 0.160 | 2 | 0.071 | 24 | 0.123 |
|  | **\*1/\*2** | NM | 0 | 0.000 | 2 | 0.028 | 2 | 0.056 | 3 | 0.120 | 3 | 0.107 | 10 | 0.051 |
|  | **\*1/\*2, CN >=3** | UM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.040 | 1 | 0.036 | 2 | 0.010 |
|  | **\*1/\*4** | IM | 0 | 0.000 | 2 | 0.028 | 1 | 0.028 | 0 | 0.000 | 4 | 0.143 | 7 | 0.036 |
|  | **\*1/\*5** | IM | 0 | 0.000 | 2 | 0.028 | 1 | 0.028 | 1 | 0.040 | 0 | 0.000 | 4 | 0.021 |
|  | **\*1/\*6** | IM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.036 | 1 | 0.005 |
|  | **\*1/\*10** | NM | 4 | 0.118 | 3 | 0.042 | 2 | 0.056 | 2 | 0.080 | 2 | 0.071 | 13 | 0.067 |
|  | **\*1/\*14** | NM | 0 | 0.000 | 1 | 0.014 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.005 |
|  | **\*1/\*29** | NM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.036 | 1 | 0.005 |
|  | **\*1/\*36** | IM | 3 | 0.088 | 3 | 0.042 | 5 | 0.139 | 4 | 0.160 | 0 | 0.000 | 15 | 0.077 |
|  | **\*1/\*41** | NM | 1 | 0.029 | 2 | 0.028 | 1 | 0.028 | 0 | 0.000 | 2 | 0.071 | 6 | 0.031 |
|  | **\*1/\*41, CN >=3** | UM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.040 | 0 | 0.000 | 1 | 0.005 |
|  | **\*2/\*2** | NM | 0 | 0.000 | 1 | 0.014 | 1 | 0.028 | 1 | 0.040 | 1 | 0.036 | 4 | 0.021 |
|  | **\*2/\*4** | IM | 0 | 0.000 | 0 | 0.000 | 1 | 0.028 | 0 | 0.000 | 2 | 0.071 | 3 | 0.015 |
|  | **\*2/\*5** | IM | 0 | 0.000 | 0 | 0.000 | 1 | 0.028 | 1 | 0.040 | 0 | 0.000 | 2 | 0.010 |
|  | **\*2/\*10** | NM | 4 | 0.118 | 4 | 0.056 | 4 | 0.111 | 0 | 0.000 | 1 | 0.036 | 13 | 0.067 |
|  | **\*2/\*14** | NM | 0 | 0.000 | 1 | 0.014 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.005 |
|  | **\*2/\*36** | IM | 2 | 0.059 | 4 | 0.056 | 2 | 0.056 | 0 | 0.000 | 1 | 0.036 | 9 | 0.046 |
|  | **\*2/\*41** | NM | 0 | 0.000 | 4 | 0.056 | 0 | 0.000 | 0 | 0.000 | 1 | 0.036 | 5 | 0.026 |
|  | **\*4/\*4** | PM | 0 | 0.000 | 1 | 0.014 | 1 | 0.028 | 0 | 0.000 | 1 | 0.036 | 3 | 0.015 |
|  | **\*4/\*5** | PM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.040 | 0 | 0.000 | 1 | 0.005 |
|  | **\*4/\*9** | IM | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.036 | 1 | 0.005 |
|  | **\*4/\*10** | IM | 0 | 0.000 | 1 | 0.014 | 1 | 0.028 | 0 | 0.000 | 0 | 0.000 | 2 | 0.010 |
|  | **\*5/\*10** | IM | 0 | 0.000 | 2 | 0.028 | 0 | 0.000 | 1 | 0.040 | 0 | 0.000 | 3 | 0.015 |
|  | **\*5/\*41** | IM | 2 | 0.059 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 2 | 0.010 |
|  | **\*10/\*10** | IM | 3 | 0.088 | 1 | 0.014 | 2 | 0.056 | 0 | 0.000 | 2 | 0.071 | 8 | 0.041 |
|  | **\*10/\*10, CN >=3** | IM | 0 | 0.000 | 1 | 0.014 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 1 | 0.005 |
|  | **\*10/\*36** | IM | 9 | 0.265 | 28 | 0.389 | 5 | 0.139 | 4 | 0.160 | 1 | 0.036 | 47 | 0.241 |
|  | **\*10/\*41** | IM | 0 | 0.000 | 1 | 0.014 | 0 | 0.000 | 1 | 0.040 | 0 | 0.000 | 2 | 0.010 |
|  | **\*36/\*41** | IM | 0 | 0.000 | 1 | 0.014 | 1 | 0.028 | 0 | 0.000 | 1 | 0.036 | 3 | 0.015 |
| **†**"Obs" and "Freq" are abbreviations for "Observations" and "Frequency" respectively. ‡"NM, "IM, "PM" and "UM" are abbreviations for "Normal Metabolizer", "Intermediate Metabolizer", "Poor Metabolizer" and "Ultrarapid Metabolizer" respectively.  |

1. **Supplementary Information**

**Supplementary Table 1.** Observed Genotype-Level Call Rates Per Variant Per Gene Per Platform, With Counts Of Successful And No Calls

**Supplementary Table 2.** Observed Diplotype-Level Call Rates Per Gene Per Platform, With Counts Of Successful And No Calls

**Supplementary Table 3.** Precision Analysis Of Nala PGx Coretm

**Supplementary Table 4.** Observed allele frequencies by ethnicity

**Supplementary Table 5.** *CYP2D6* Intron 2 And Exon 9 Observations And Frequencies By Ethnicity

**Supplementary Table 6.** *CYP2D6\*36* Observations And Frequencies By Ethnicity

**Supplementary Table 7.** Diplotype Calls Observed Across All Samples Tested On Agena Veridose® Core And *CYP2D6* CNV Panel And Nala PGx Core™

**Supplementary Table 8.** Raw And Reported Diplotype Concordance Values For Samples Tested On Agena Veridose® Core And CYP2D6 CNV Panel And Nala PGx Core™

**Supplementary Tables 9.1 to 9.18.** Raw genotype calls for rs1799853, rs1057910, rs4244285, rs4986893, rs12248560, rs1065852, rs5030655, rs3892097, rs35742686, rs16947, rs28371725, rs1135840, rs769258, rs5030865, rs5030656, rs59421388 and rs267608319, on Nala PGx Core™ and the corresponding benchmark methods, Agena VeriDose® Core and *CYP2D6* CNV Panel or TaqMan® DME Genotyping Assays

**Supplementary Table 9.19.** Raw variant calls for *CYP2D6* Intron 2 and Exon 9 on Agena VeriDose® Core and *CYP2D6* CNV Panel and Nala PGx Core™

**Supplementary Figure 1.** **Observed *CYP2D6* Functional Copy Number Frequencies By Ethnicity.** Distribution of individuals carrying one, two or three or more copies of the *CYP2D6* functional gene among the study cohort (n=205), grouped per ethnicity.